Furthermore, triple therapy with BRAF + EGFR + SRC inhibitors significantly improved tumor growth inhibition compared to any doublet (Fig. 3f,g; GLM standard coefficients >0.8 and >0.5 for cell line xenografts and PDXs, respectively; false discovery rate (FDR)-corrected P values in Extended Data Fig. 3f and in the right panel of Fig. 3g). The gene discussed is BRAF; the disease is neoplasm.